Acetylsalicylic acid (Aspirin, BAYE4465) + Acetylsalicylic acid (Aspirin, BAYE4465) + Ibuprofen + Ibuprofen + Placebo

ApprovedCompleted
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Headache

Conditions

Headache, Tension-Type Headache, Tension-Type Headache (Episodic)

Trial Timeline

Jan 1, 2004 → Aug 1, 2004

About Acetylsalicylic acid (Aspirin, BAYE4465) + Acetylsalicylic acid (Aspirin, BAYE4465) + Ibuprofen + Ibuprofen + Placebo

Acetylsalicylic acid (Aspirin, BAYE4465) + Acetylsalicylic acid (Aspirin, BAYE4465) + Ibuprofen + Ibuprofen + Placebo is a approved stage product being developed by Bayer for Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT01464983. Target conditions include Headache, Tension-Type Headache, Tension-Type Headache (Episodic).

What happened to similar drugs?

8 of 20 similar drugs in Headache were approved

Approved (8) Terminated (1) Active (11)
🔄DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
🔄Galcanezumab 300 mg + PlaceboEli LillyPhase 3
🔄GalcanezumabEli LillyPhase 3
Galcanezumab-GnlmEli LillyApproved
🔄Galcanezumab + PlaceboEli LillyPhase 3
🔄topiramateJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01464983ApprovedCompleted

Competing Products

20 competing products in Headache

See all competitors
ProductCompanyStageHype Score
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Placebo + LY2300559Eli LillyPhase 2
27
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Aricept (donepezil hydrochloride)EisaiPhase 2
35
Galcanezumab 300 mg + PlaceboEli LillyPhase 3
40
GalcanezumabEli LillyPhase 3
40
Galcanezumab-GnlmEli LillyApproved
43
LY2590443 + Placebo injection + Sumatriptan + Placebo capsuleEli LillyPhase 2
27
LY2951742 + PlaceboEli LillyPhase 2
35
Galcanezumab + PlaceboEli LillyPhase 3
40
Galcanezumab + PlaceboEli LillyPhase 2
35
Soy IsoflavonesJohnson & JohnsonPre-clinical
26
topiramateJohnson & JohnsonPhase 3
40
Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
47
Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
43
candesartan cilexetil + placeboAstraZenecaPhase 2
35
Rizatriptan + PlaceboMerckPre-clinical
18
Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
43
AMG 334NovartisPhase 2
35